Vir Biotechnology Inc expected to post a loss of 87 cents a share - Earnings Preview

Vir Biotechnology

01/05/2023 12:55

* Vir Biotechnology Inc  VIR.OQ   VIR.O  is expected to show
a
fall in quarterly revenue when it reports  results on May 3
(estimated). 
    * The San Francisco California-based  company is expected to
report  a 95.9% decrease in revenue to $50.099 million from
$1.23 billion a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Vir Biotechnology
Inc is
for a loss of 87 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vir
Biotechnology
Inc is $43​, above​ its last closing price of $25.15. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.25       -0.39      -0.76     Missed  -92.4
 Sep. 30 2022  -0.21       -0.21      1.30      Beat    710.3
 Jun. 30 2022  0.16        0.10       -0.58     Missed  -653.7
                                                        ​
 Mar. 31 2022  3.83        3.78       3.85      Beat    1.9
 ​​Dec.        4.42        3.04       3.92      Beat    28.9
 31 2021                                                
 Sep. 30 2021  0.04        0.02       0.82      Beat    3,487.
                                                        1​
 Jun. 30 2021  -0.57       -0.48      0.46      Beat    196.4
 Mar. 31 2021  -0.14       -0.21      -1.32     Missed  -520.1
 This summary was machine generated May 1 at 11:55 GMT.  All
figures in US dollars  unless otherwise stated